A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease

Charles Flicker, Steven H. Ferris, Davina Kalkstein, Michael Serby

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.

Original languageEnglish
Pages (from-to)126-129
Number of pages4
JournalAmerican Journal of Psychiatry
Volume151
Issue number1
DOIs
StatePublished - Jan 1994
Externally publishedYes

Fingerprint

Dive into the research topics of 'A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this